Groowe Groowe / Newsroom / CGEN
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CGEN News

Compugen Ltd

Immuno-Oncology Drugs Market Projected to Reach US$ 185.69 Billion by 2035 | Astute Analytica

globenewswire.com
VRTX MRK BMY GILD JNJ AZN NVS REGN AMGN PFE BIIB ISRG MDLZ IMCR CRSP EDIT NCLH ACRS ALNY INCY ABBV LULU EXAS RDVY ONCY GENM DTIL XAIR CGEN ADPT ATRC CODX CORT CRBU CTAS CYTK DASH DECK DOCU EBAY ELAN ENPH EPAM FIVN FORM FTNT GDRX GEHC GNTX GOOS GRMN GTLB HGV HLT HOLX HON HPE HPQ HRB HSIC HWM IDXX ILMN INSM INTC INTU IRTC ITRI IVZ JBL JEF JHG JLL JPM KDP KHC KODK LAKE LCID LRCX LSCC LYFT MCHP MELI MGM MKTX MLCO MNST MRVL MTCH MU NDSN NEO NET NFLX NKE NOC NOW NRG NTAP NTES NVDA NXPI ODFL OMC ON ORCL ORLY OSK OTIS OXY PANW PAYX PCAR PCG PDD PEP PGR PH PHG PII PKX PLAB PLD PLUG PM PNW POOL POST PPG PPL PRGS PRGO PRLB PRO PRTA PSFE PSNY PTC PVH QCOM QGEN QRVO RBLX RCL RDNT REI REIT RF RGEN RIVN RL RMBS RMD ROBT ROKU ROST RPRX RS RSG RSP RVSN RYAAY S SABR SAN SAVA SBAC SBRA SBUX SCHD SCL SD SE SEDG SEE SEIC SELF SEM SIRI SJM SKX SLB SLGN SMCI SMLR SNBR SNOW SNPS SO SONO SPCE SPGI SPNS SQM SRPT SSNC ST STAG STLD STNG STOK STX SUN SWKS SYK SYY T TAL TAN TCOM TDOC TECK TEF TEK TEL TER TFX TGT TGTX THC THO TIGR TITN TJX TLRY TMO TMUS TNDM TNET TOL TOPS TORO TPH TPL TQQQ TR TRC TRIP TRMB TRMK TRN TRP TRT TRVG TS TSCO TSE TSLA TSN TT TTC TTD TTI TTNP TTWO TU TUSK TV TVC TVE TW TWLO TX TXN TXRH TXT TYL U UAL UBER UDR UEC UHAL ULTA UMC UMH UNFI UNH UNIT UNM UPST URBN USA USFD USNA USPH UTHR V VRSK VTR VTRS VZ W WAB WDC WEC WELL WEN WERN WEX WFC WGO WHD WHR WIA WMB WMT WNS WPC WRB WST WTAI WTFC WTS WU WY WYNN XBIT XCUR XENE XFLT XGN XHR XLP XOM XPO XRAY XRT XTLB XXII XYL YETI YMM YPF YUM Z ZBRA ZCMD ZIM ZION ZKIN ZNTL ZTO ZTS ZYME

TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines

globenewswire.com
GILD MRK ARCX CGEN VIR

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

prnewswire.com
CGEN

Compugen Reports Third Quarter 2025 Results

prnewswire.com
CGEN

Compugen to Participate in Stifel 2025 Healthcare Conference

prnewswire.com
CGEN

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

prnewswire.com
CGEN

DATROWAY ® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial

businesswire.com
CGEN

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

prnewswire.com
CGEN

Compugen to Present at SITC 2025

prnewswire.com
CGEN

Q3 Virtual Investor Summit: On-Demand Presentations Now Available

accessnewswire.com
JG CGEN COE GCTK MRAM PRSO UXIN SPCB MIND